Catherine Knupp - Zoetis President of RandD and Executive VP

ZTS -- USA Stock  

USD 123.07  3.57  2.82%

Dr. Catherine A. Knupp is Executive Vice President, President Research and Development of Zoetis Inc. Dr. Knupp has served as our Executive Vice President and President of Research and Development since October 2012. From 2005 to 2012, she served as Vice President of Pfizers Veterinary Medicine Research and Development business unit. Dr. Knupp joined Pfizer in July 2001 and held various positions, including Vice President of Pfizers Michigan laboratories for Pharmacokinetics, Dynamics and Metabolism.
Age: 57  President Since 2012  Ph.D    
Knupp earned her Doctor of Veterinary Medicine degree in 1985 from the University of Illinois, where she also received a master degree in toxicology and a bachelor degree in veterinary biosciences. She also earned another bachelor degree in chemistry from Western Illinois University.

Catherine Knupp Latest Insider Activity

Management Efficiency

The company has Return on Asset of 12.56 % which means that on every $100 spent on asset it made $12.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 62.6 % implying that it generated $62.6 on every 100 dollars invested.
The company has 6.65B in debt with debt to equity (D/E) ratio of 275.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.09 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Amit SachdevVertex Pharmaceuticals Incorpor
Douglas BoothePerrigo Company plc
Jeffrey NeedhamPerrigo Company plc
Raghav ChariDr Reddys Laboratories Ltd
John WesolowskiPerrigo Company plc
Michael PariniVertex Pharmaceuticals Incorpor
John HendricksonPerrigo Company plc
Sripada ChandrasekharDr Reddys Laboratories Ltd
Samiran DasDr Reddys Laboratories Ltd
Kimberly WhiteVertex Pharmaceuticals Incorpor
Paul WeningerPerrigo Company plc
Grainne QuinnPerrigo Company plc
Umang VohraDr Reddys Laboratories Ltd
Christopher FenimoreRegeneron Pharmaceuticals
John GrayVertex Pharmaceuticals Incorpor
Marion McCourtRegeneron Pharmaceuticals
Ian SmithVertex Pharmaceuticals Incorpor
Charles WagnerVertex Pharmaceuticals Incorpor
James MichaudPerrigo Company plc
Michael StewartPerrigo Company plc
Douglas McCorkleRegeneron Pharmaceuticals

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive VP and President of U.S. Operations
William Steere, Independent Director
Roxanne Lagano, Chief Human Resource Officer, Executive Vice President
Linda Rhodes, Director
Frank DAmelio, Director
Robert Scully, Independent Director
Clinton Lewis, Executive VP and President of International Operations
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, President of RandD and Executive VP
Michael McCallister, Non-Executive Chairman of the Board
Paul Bisaro, Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Acting CFO and Sr. VP
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President CIO
Gregory Norden, Independent Director
Louise Parent, Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, CEO and Director

Stock Performance Indicators

Current Sentiment - ZTS

Zoetis Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Zoetis. What is your take regarding investing in Zoetis? Are you bullish or bearish?
98% Bullish
2% Bearish

Also Currentnly Active

Purchased over 70 shares of
few hours ago
Traded for 36.96
Purchased over 40 shares of
few hours ago
Traded for 62.36
Purchased over 70 shares of
few hours ago
Traded for 36.96
See also Your Current Watchlist. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.